Pierre Fabre reveals management restructure

Bertrand Parmentier has joined the company as CEO

Following the death of Pierre Fabre on 20 July, his eponymous pharmaceutical and cosmetics company has introduced a new management structure. The move is said to reflect Fabre’s desire to maintain the company’s independence.

In line with the restructure, Pierre-Yves Revol has been appointed Chairman of the company while Jean-Jacques Bertrand, board member of Pierre Fabre SA, becomes Chairman of the company’s board of directors.

Meanwhile, Bertrand Parmentier, who previously worked for Pierre Fabre Laboratories between 1991-2008 as Finance Director, has joined the company as CEO. He was most recently CEO of the Latécoère aircraft company.

Finally, Jean-Luc Belingard has been appointed as a board member of the company, while Eric Ducournau will head up the company’s Dermo-cosmetics business as President and CEO, while Frédéric Duchesne will lead the Pharmaceuticals business as President and CEO.

You may also like

Ingredients

Pierre Fabre signs partnership with SETUBIO as part of the Nature Open Library programme

SETUBIO will explore the plant collection made available by Pierre Fabre to develop new actives for human and animal health
Ingredients

Pierre Fabre and VibioSphen agree new Nature Open Library partnership

Collaboration aims to develop naturally derived compounds to combat antibiotic resistant bacteria
Drug Delivery

Cellectar and Pierre Fabre announce oncology research collaboration

Collaboration will advance the use of Cellectar’s phospholipid drug conjugate (PDC) platform to improve the delivery of Pierre Fabre’s cytotoxics
Pharmaceutical

High-precision temperature control solutions for the pharmaceutical industry and biotechnology, available in the UK from Labtex

Huber offers a world-renowned range of temperature control systems and associated accessories for the Pharmaceutical Industry and Biotechnology
Sustainability

Building strong foundations for a resilient and planet-friendly future

Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
Sustainability

Dickson achieves ISO 14001 certification

ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
Regulatory

The key role of IVDs in healthcare: challenges to commercialisation and access

In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and infections, provide patients with a better understanding of their ailment and how it might be managed and changed with treatment
Subscribe now